HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates of Virologic Suppression Despite Adherence Rates Less Than 95%
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The observation that extremely high levels of medication adherence are required to achieve complete virologic suppression is based largely on studies of treatment-experienced patients receiving HIV protease inhibitor (PI)-based therapy without ritonavir boosting. This study aims to define the level of adherence needed to achieve virologic suppression in patients receiving boosted PI-based highly active antiretroviral therapy (HAART) with lopinavir/ritonavir. METHODS: HIV-infected adults receiving a regimen containing lopinavir/ritonavir were recruited into a prospective, observational study of the relation between adherence to lopinavir/ritonavir and virologic outcomes. Adherence was measured using the Medication Event Monitoring System (MEMS; Aardex, Union City, CA). HIV-1 viral load (VL) was measured at week 24. RESULTS: The final study population contained 64 subjects. Eighty percent had AIDS, 97% received lopinavir/ritonavir before enrollment, and most had more than 7 years of HAART experience. Mean adherence overall was 73%. Eighty percent and 59% achieved a VL <400 copies/mL and a VL <75 copies/mL, respectively. Mean adherence was 75% in those achieving a VL <75 copies/mL. High rates of virologic suppression were observed in all adherence quartiles, including the lowest quartile (range of adherence: 23.5%-53.3%). CONCLUSIONS: Moderate levels of adherence can lead to virologic suppression in most patients taking lopinavir/ritonavir-based HAART.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428 · cited 1×
“At the week 24 study visit, subjects completed a previously validated Adult AIDS Clinical Trial Group (AACTG) adherence instrument, which quantitates adherence by 4-day recall.(10) Subjects who completed the baseline and week 24 visits and who had VL measurements at both time points were entered into the final analysi…”
Method
Cited by
Finitsis, D. J., Pellowski, J. A., & Johnson, B. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088166 · Cited by 355
“, less than 95%) adherence levels [61,62].”
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
Haberer, J. E., Bangsberg, D. R., Baeten, J. M., Curran, K., Koechlin, F., Amico, K. R., Anderson, P., Mugo, N., Venter, F., Goicochea, P., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000647 · Cited by 319
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts
B. Nachega, J., C. Marconi, V., U. van Zyl, G., M. Gardner, E., Preiser, W., Y. Hong, S., J. Mills, E., & Gross, R. (2011) · Infectious Disorders - Drug Targets · doi:10.2174/187152611795589663 · Cited by 271
Bärnighausen, T., Chaiyachati, K., Chimbindi, N., Peoples, A., Haberer, J., & Newell, M.-L. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70181-5 · Cited by 246
Dale, S., Cohen, M., Weber, K., Cruise, R., Kelso, G., & Brody, L. (2014) · AIDS Patient Care and STDs · doi:10.1089/apc.2013.0329 · Cited by 135
Metadata
- Authors
- Shuter, J., Sarlo, J. A., Kanmaz, T. J., Rode, R. A., & Zingman, B. S.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2007-05-01
- Volume
- 45
- Issue
- 1
- Pages
- 4-8
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2074524403
- Cited by
- 151
- References
- 1
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates of Virologic Suppression Despite Adherence Rates Less Than 95%. https://app.cochat.ai/papers/10.1097/qai.0b013e318050d8c2
- The paper
- Shuter, J., Sarlo, J. A., Kanmaz, T. J., Rode, R. A., & Zingman, B. S. (2007). HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates of Virologic Suppression Despite Adherence Rates Less Than 95%. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0b013e318050d8c2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.